KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	11.71B
Revenue (ttm)	8.08B
Net Income (ttm)	607.32M
Shares Out	756.98M
EPS (ttm)	0.81
PE Ratio	19.08
Forward PE	15.89
Dividend	0.30 (1.94%)
Ex-Dividend Date	Jul 31, 2024

Volume	11,202,583
Average Volume	10,546,642
Open	15.39
Previous Close	15.41
Day's Range	15.18 - 15.57
52-Week Range	11.92 - 21.52
Beta	0.20
RSI	37.00
Earnings Date	Aug 22, 2025

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotic, immunosuppressive, and others. The company provides medicine and food, skin care, oral care, private care, and time-honored food series; and other products, such as oral medication ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,275
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2024, KPC Pharmaceuticals,Inc.'s revenue was 8.40 billion, a decrease of -0.34% compared to the previous year's 8.43 billion. Earnings were 648.08 million, an increase of 19.86%.